Tivic Health Systems, Inc. (TIVC) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Tivic Health Systems, Inc. (TIVC) Healthcare & Pipeline Overview

Tivic Health Systems Inc. develops and commercializes bioelectronic devices, with ClearUP as its flagship product for sinus inflammation relief. The company utilizes a direct-to-consumer and online retail distribution model in the medical device sector, facing competition from established pharmaceutical and medical device companies.

What Is the Investment Thesis for TIVC?

Tivic Health Systems operates in the emerging bioelectronic medicine field with its ClearUP device targeting sinus inflammation. The company's direct-to-consumer sales model offers potential for high margins, but also requires significant marketing investment. With a market capitalization of $0.00B and negative gross margins of -58.1%, Tivic Health faces challenges in achieving profitability. The company's high beta of 2.01 indicates significant volatility. Future success depends on expanding market share, demonstrating clinical efficacy, and achieving sustainable revenue growth. Investors should closely monitor sales figures, marketing expenses, and regulatory developments.

Based on FMP financials and quantitative analysis

TIVC Key Highlights

Market capitalization of $0.00B, indicating a micro-cap company with high growth potential but also significant risk.

• Negative gross margin of -58.1%, reflecting high cost of goods sold relative to revenue and highlighting the need for improved operational efficiency.
• Return on Equity (ROE) of -178.2%, suggesting inefficient use of equity financing and significant losses.
• Negative Free Cash Flow (FCF) of $-0.00B, indicating the company is currently burning cash and may need additional funding.
• Beta of 2.01, indicating the stock is more volatile than the market and subject to greater price swings.

Who Are TIVC's Competitors?

TIVC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are TIVC's Key Strengths?

Innovative neuromodulation technology.

• Direct-to-consumer sales channel.
• Focus on non-invasive treatment.
• Established online retail partnerships.

What Are TIVC's Weaknesses?

Negative gross margins.

• Limited product portfolio.
• Small market capitalization.
• High beta indicating volatility.

What Could Drive TIVC Stock Higher?

Potential FDA clearance for new indications of ClearUP device.

• Expansion of direct-to-consumer marketing efforts to increase sales.
• Development of strategic partnerships with healthcare providers.

What Are the Key Risks for TIVC?

Financial-distress signal — its Altman Z-Score of -4.54 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Regulatory challenges and delays in obtaining approvals.
• Competition from established pharmaceutical companies.
• Negative gross margins and cash burn.
• Dependence on a single product (ClearUP).

What Are the Growth Opportunities for TIVC?

• Expansion into new markets represents a significant growth opportunity for Tivic Health. By targeting international markets with high prevalence of sinus and nasal inflammation, the company can increase its customer base and revenue streams. This expansion could involve partnerships with international distributors or establishing a direct-to-consumer presence in key regions. Timeline: within the next 2-3 years.
• Development of new products targeting other inflammatory conditions beyond sinus inflammation offers a pathway for diversification and revenue growth. By leveraging its expertise in neuromodulation technology, Tivic Health can expand its product portfolio to address conditions such as allergies, headaches, and musculoskeletal pain. This expansion would require further research and development, as well as clinical trials to demonstrate efficacy and safety. The market for neuromodulation devices is growing rapidly, driven by increasing demand for non-pharmacological pain management solutions. Timeline: within the next 3-5 years.
• Strategic partnerships with healthcare providers and insurance companies can drive adoption of ClearUP and other Tivic Health products. By collaborating with ENT specialists, allergists, and primary care physicians, the company can increase awareness and referrals for its devices. Securing reimbursement coverage from insurance companies would also significantly improve affordability and accessibility for patients. These partnerships would require demonstrating the clinical and economic value of Tivic Health's products through clinical trials and health economic studies. Timeline: ongoing.
• Enhancing the ClearUP device with advanced features and connectivity can improve user experience and drive repeat purchases. Integrating sensors to track sinus inflammation levels and providing personalized treatment recommendations through a mobile app could enhance the value proposition of ClearUP. This would require investment in software development and data analytics capabilities. The market for connected medical devices is growing rapidly, driven by increasing demand for remote monitoring and personalized healthcare solutions. Timeline: within the next 1-2 years.
• Increasing brand awareness through targeted marketing campaigns can drive sales and build customer loyalty. By leveraging social media, online advertising, and influencer marketing, Tivic Health can reach a wider audience and educate consumers about the benefits of ClearUP. This would require a significant investment in marketing and public relations. The direct-to-consumer market is highly competitive, so effective marketing is crucial for differentiating Tivic Health's products and building brand recognition. Timeline: ongoing.

What Threats Does TIVC Face?

• Competition from established pharmaceutical companies.
• Regulatory hurdles for medical devices.
• Changing consumer preferences.
• Economic downturn affecting consumer spending.

What Are TIVC's Competitive Advantages?

• Proprietary neuromodulation technology.
• Direct-to-consumer sales channel.
• Established partnerships with online retailers.
• Focus on a specific niche market (sinus inflammation).

What Does TIVC Do?

Tivic Health Systems Inc., founded in 2016 and headquartered in Fremont, California, operates as a bioelectronic device company focused on delivering non-invasive neuromodulation products. The company's core innovation lies in addressing inflammatory conditions through targeted electrical stimulation, offering an alternative to traditional pharmaceutical interventions. Its primary product, ClearUP, is a medical device designed to relieve sinus and nasal inflammation. ClearUP employs microcurrent waveforms to stimulate sinus nerves, aiming to reduce inflammation and congestion. Tivic Health sells ClearUP directly to consumers through its own websites and via online platforms like Amazon.com and Walmart.com. The company also partners with U.S. online retailers, including BestBuy.com and FSAStore.com, to expand its market reach. This direct-to-consumer approach allows Tivic Health to control its brand messaging and customer experience, while online retail partnerships provide access to a broader customer base. The company's focus on non-invasive neuromodulation positions it within a growing segment of the medical device industry that seeks to provide patients with drug-free alternatives for managing chronic conditions.

What Products and Services Does TIVC Offer?

• Develops and commercializes bioelectronic devices.
• Offers non-invasive neuromodulation products.
• Focuses on treating inflammatory conditions.
• Markets ClearUP for sinus and nasal inflammation relief.
• Sells products directly to consumers through its website.
• Distributes products through online retailers like Amazon and Walmart.

How Does TIVC Make Money?

• Direct-to-consumer sales through its own websites.
• Partnerships with online retailers.
• Revenue generated from sales of ClearUP device.
• Focus on non-invasive neuromodulation for inflammatory conditions.

What Industry Does TIVC Operate In?

Tivic Health Systems operates within the medical device industry, specifically targeting the neuromodulation segment. This market is characterized by increasing demand for non-invasive and drug-free treatment options. The competitive landscape includes established pharmaceutical companies offering traditional sinus medications, as well as other medical device companies developing alternative neuromodulation technologies. Tivic Health's direct-to-consumer approach differentiates it from some competitors, but also requires significant investment in marketing and customer acquisition.

Who Are TIVC's Key Customers?

• Individuals suffering from sinus and nasal inflammation.
• Consumers seeking drug-free alternatives for symptom relief.
• Customers purchasing through online channels.
• Patients looking for non-invasive treatment options.

Company Profile

Tivic Health Systems, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Fremont, US. The company is led by CEO Michael Kevin Handley. TIVC has traded publicly since 2021.

Key Financial Metrics

Return on assets is -35.5%, showing how much profit it generates from its asset base. A current ratio of 3.31 indicates the company holds enough short-term assets to cover its near-term obligations.

Tivic Health Systems, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -4.54 places it in the distress zone, a signal of elevated financial risk.

TIVC Financials

TIVC Latest News

No recent news available for TIVC.

TIVC Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources